An observational study in Desmoid Tumor and Aggressive Fibromatoses, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Mayo Clinic · Observational
This study will evaluate patient-reported outcomes before and after percutaneous ablation of desmoid tumors. Adult participants undergoing ablation for desmoid tumor will complete surveys pre and post procedure to assess symptom burden, impact on daily life, early post-procedural pain and recovery, concomitant treatments, and radiological response following ablation.
71 studies on the registry are indexed under Desmoid Tumors; 21 are open to participants now.
This study's planned enrollment of 30 is below the median of 100 across 19 observational studies indexed under Desmoid Tumors.
Browse Desmoid Tumors studies →Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients undergoing ablation of desmoid tumor at Mayo Clinic Rochester.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult participants undergoing percutaneous ablation for desmoid tumor who complete patient-reported outcome surveys before and after treatment.
Procedure: Desmoid tumor ablation
Percutaneous ablation of desmoid tumor
Change in desmoid tumor symptom severity following ablation
Desmoid tumor symptom severity following ablation will be measured using the GODDESS© Desmoid Tumor Symptom Scale, a disease-specific patient-reported outcome measure assessing desmoid tumor-related symptoms. Scores will be calculated according to the validated GODDESS© scoring algorithm. Higher scores indicate greater symptom burden.
Time frame: Baseline; 7 days; 1, 3, 6, 12, and 24 months post-ablation
Change in desmoid tumor impact following ablation
Desmoid tumor impact following ablation will be measured using the GODDESS© Desmoid Impact Scale, a disease-specific patient-reported outcome measure assessing desmoid tumor-related symptoms on patients' daily lives and functioning. Scores will be calculated according to the validated GODDESS© scoring algorithm. Higher scores are expected to indicate greater disease-related impact.
Time frame: Baseline; 7 days; 1, 3, 6, 12, and 24 months post-ablation
Change in post-procedural pain score
The pain score is calculated from a 2 question self-report survey asking recipients to rate pain on a scale of 1-10. Higher scores indicate worse pain.
Time frame: Baseline; 7 days; 1 month and 3 months post-ablation
Radiological response following ablation
Radiologic assessment of desmoid tumor response on follow-up imaging, including tumor response characteristics as available in the medical record.
Time frame: Through 24 months post-ablation
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Sep 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.